Entropy Technologies’s Novavax NVAX Stock Holding History

Entropy Technologies’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-29,739	Closed	-$191K	–	950
2025 Q1	$191K	Buy	+29,739	New	+$246K	0.02%	634
2024 Q4	–	Sell	-12,499	Closed	-$158K	–	913
2024 Q3	$158K	Buy	+12,499	New	+$161K	0.02%	656

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Entropy Technologies's NVAX Position: Q2 2025 in Review

Entropy Technologies sold out of Novavax (NVAX) in Q2 2025, closing a stake of 29,739 shares — an estimated $191K sold.

Entropy Technologies first reported a position in NVAX in Q3 2024 and held it in 2 quarters. The position peaked at $191K in Q1 2025. 250 funds tracked by Wall St. Rank hold NVAX as of Q2 2025.

Entropy Technologies reported no remaining Novavax position as of Q2 2025 after selling out during the quarter.
Entropy Technologies sold 29,739 Novavax shares in Q2 2025, an estimated $191K.
Entropy Technologies first reported a position in Novavax in Q3 2024 and held it in 2 quarters.
Entropy Technologies's Novavax position peaked at $191K in Q1 2025.
250 funds tracked by Wall St. Rank held Novavax as of Q2 2025.

Based on Entropy Technologies's 13F filing for Q2 2025, filed 12 Aug 2025.